ArticleCurrent molecular medicine2026
Effects of the Total Flavonoids from
Article in Current molecular medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
introductionThis study aimed to investigate the effects of the Total Flavonoids from Rhizoma Drynaria (TFRD) on METTL3-mediated m6A methylation and osteogenic-angiogenic coupling during the repair of large bone defects and to elucidate its role in bone remodeling under the Masquelet technique.
methodsA large femoral bone defect rat model was established in Sprague Dawley (SD) rats using the Masquelet technique. Postoperatively, a total of 24 rats were randomly divided into four groups, namely the model group (MOD), low-dose group (0.11 g/kg/day), mid-dose group (0.22 g/kg/day), and high-dose group (TFRD) (0.44 g/kg/day). These groups were established using the corresponding TFRD dosages or saline interventions. The neobone tissue quality was assessed using X-rays (Lane- Sandhu score), and the bone volume fraction (BV/TV) and trabecular thickness (Tb.Th) were quantified using micro-computed tomography (micro-CT). The localization and expression of type H vessel markers (CD31, EMCN) and measurement of the total RNA m6A methylation levels in the neobone tissues were performed using Immunohistochemistry (IHC). The osteogenic-angiogenic coupling factors (BMP-2, PDGF-BB, S1P) and m6A methylation regulators (METTL3, IGF2BP2) were analyzed using a western blot and qRT-PCR.
resultsThe micro-CT and X-ray techniques revealed that TFRD significantly enhanced the neobone tissue quality, increased the BV/TV, and thickened Tb.Th compared to the MOD group. IHC showed a dose-dependent upregulation of the CD31 and EMCN expression areas and intensity in the neobone tissues, in addition to elevated m6A methylation levels with increasing TFRD doses. The western blot showed that the osteogenic-angiogenic coupling proteins (PDGF-BB, S1P, BMP-2) and m6A regulators (METTL3, IGF2BP2) were upregulated in a dose-dependent manner. Notably, while qRT-PCR indicated that TFRD suppressed PDGF-BB mRNA expression, the protein level was elevated, suggesting potential post-transcriptional regulation. The mRNA levels of BMP-2, S1P, METTL3, and IGF2BP2 were enhanced. DISCUSSION: This study suggests that TFRD promotes bone regeneration not only by enhancing osteogenic and angiogenic factor expression but also through epitranscriptomic regulation via the METTL3-m6A axis. The discordance between PDGF-BB mRNA and protein levels implies a potential post-transcriptional regulatory mechanism, possibly mediated by m6A modification, which merits further investigation. This study provides novel insights into the pharmacological mechanism of TFRD, positioning it as a promising candidate for adjunctive therapy in bone defect repair.
conclusionTFRD facilitated bone regeneration by modulating METTL3-mediated m6A methylation, upregulating osteogenic-angiogenic coupling factors, and stimulating type H vessel formation. These findings support the potential of TFRD as a promising therapeutic agent for bone defect repair. TFRD acted through mechanisms that involve RNA methylation and enhanced the interaction between osteogenesis and angiogenesis. Targeting the epitranscripto-mic regulation of bone-vascular interaction may open new avenues for orthopedic rehabilitation.
Indexed as
Identifiers
41239929What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.